Proyecto de implantación de PROMs en Oncohematología

Quality Training Program

Madrid 2020





ASCO's Quality Training Program

Project Title: Implementation of a PROM tool in patients with hematological malignancies in the Lymphoma and Chronic Lymphocytic Leukemia program

Presenter's Name: Eva Castillo, Raul Cordoba

Institution: Fundacion Jimenez Diaz University Hospital, Madrid, Spain

Date of Storyboard Presentation: 14 december 2020





Institutional Overview

- Fundacion Jimenez Diaz is an academic hospital linked to University Autonomous Madrid.
- The facilities include an Adult Daycare Hospital, Department of Hematology and Hospital Pharmacy, certified by ASCO-QOPI in 2019, ISO 9001:2015 since 2018, EFQM since 2017 and Ad Qualitatem since 2016
- The Department of Hematology has:
 - 20 hematologist consultants
 - 8 residents (2 residents each year)
- Day Hospital: 17 armchairs, all with programmable pumps, with 31.000 i.v. annual treatments
- Hospitalization: 680 beds
- 24 hours, 7 days a week hematology on call & 14 hours, 7 days a week hospital pharmacist on call
- Emergency unit:
 - -20 boxes
 - -35 emergency doctors
 - -19 doctors on duty





Institutional Overview

Department of Hematology:

- Lymphoma Unit
- Myeloma Unit
- Myeloid malignancies Unit
- Stem Cell Transplant Unit
- Diagnostic Unit
- Blood Service Unit
- Coagulation Unit





Problem Statement

In a 3 months period (March-May 2019) we have analyzed 24 patients with lymphoid malignancies (Lymphoma, CLL), treated with antineoplastic agents in our Lymphoma Unit.

We have detected 117 moderate-severe Aes (4%), related and not related to the treatment leading to ER consultation or unscheduled hospitalization.

GRADE 2-3 AE IMPACT ON QUALITY OF CARE

- Delay or disminution of dosis in treatment: 4,27 % of total Aes
- Unscheduled visits: 25,64 % of total Aes (emergency room and visits without annotation)
- Serious complications and hospitalizations: 6,84 % of total AEs





Team Members

- Sponsor: Dr. Jesus Garcia-Foncillas: Project Manager
- Medical Team: Raul Cordoba, Daniel Morillo, Marian Perez, Javier
 Cornago, Laura Solan, Jose Luis Lopez Lorenzo: diagnosis,
 treatment and information about treatment toxicities
- Nurse Team: Sara Raba, Auxiliadora Galvan, Emilio González, Cristina Elez: treatment administration, triage call, information about treatment toxicities
- Pharmacist Team: Eva Castillo, María Arias, Elena Tortajada: information about treatment toxicities, treatment dispensation
- Receptionist: Isabel Benito, Estrella Pacheco, Pilar Pelaez: call reception
- Informatic team: Susana Cruz: solve computer problems, form creation






Data source

- EMR Casiopea: medical information system that provides the features of Electronic Medical History that includes all the information regarding the patient and his attention. It integrates with the Pharmacy, Laboratory and Medical Imaging systems.
- Farmis Oncopharm: Departmental hospital application with interdisciplinary and multiprofessional development, among health professionals for the care of onco-hematological patients. It guarantees the coordination and structuring of functions. Equipped with warning systems and support for the clinical decision.
- IMDH: is a comprehensive hospital management system that responds to the needs of operation, clinical, economic-financial and management control, integrating with the rest of the Center's systems.






Process Map Current State







Cause & Effect Diagram



Diagnostic Data

Diagnosis Data	Lymphoma (intravenous/oral)	CLL (intravenous/oral)
Total #	19	5
Aes Grade 2-4	100	11
Unscheduled Encounters	6	1
Emergency Service Visits	17	6
Hospitalization	7	1
Treatment Delay	3	1
Dose reduction	1	0






Baseline Data

HEMATOLOGICAL	45
CARDIOVASCULAR	2
GI	18
GENERAL/IRR	19
INFECTIONS	8
METABOLIC	6
MUSCULOSKELETAL	6
CNS	7
RESPIRATORIES	1
CUTANEOUS	5





Pareto chart







Aim Statement

Reduce 20% of unschedule visits to ER and hospitalizations due to AEs by means of a PROM tool to identify early side effects of treatments in patients with lymphoma and CLL





Measures: Outcome

Measure:

- Adverse events level 2-4 related and not related to antineoplastic treatments defined by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
- Number of ER visits
- Number of hospitalizations
- Number of nurse calls
- Number of uncheduled visits

Patient population:

Patients with lymphoma and CLL attendend in FJD University Hospital in a 3 month period who started to recibe active treatment for their malignancy





Measures: Outcome


- Calculation methodology: data compilation of patients who enter in the program and contrast them with the data recorded in 2019
- **Data source**: patient's clinical charts
- Data collection frequency: weekly
- Data quality (any limitations): visits not recorded
- Process Measurement:
 - # of times patient education sessions occur/# of patient visits
 - # of scheduled visit between treatment visits
 - % of phone calls/weekly questionnaires received
 - % of patients with patients portal
 - % of cumplimented questionnaires





Process Map Currently

FUTURE RECOGNITION-REPORTING-MANAGEMENT OF AES



Prioritized List of Changes (Priority/Pay –Off Matrix)

	Team involvement	Completition of PROMs questionnaires
High		Patient involvement
Impact		Data collection and analysis of patient information
Low	Team meetings	Push messages texting to remind the completition of questionnaires

Easy Difficult





PDSA Plan (Test of Change)

	Date of PDSA Cycle	Description of Intervention	Results	Action Steps
	January 2020 March 2020	Design of PROMs quiestionnaires	Identification of main problems	Information to the team about the use of questionnaires in virtual consultation
	Mach 2020 May 2020	Starting the use of PROM questionnaires by the patient	Start of non-face-to- face consultations associated with PROMs questionnaires	Periodic meetins and staff training
A S	Ongoing	Use of Patient Portal to complete PROM questionnaires by the patient	Adapt questionnaires to patient needs	Analyze results in a similar period to the first data collection
Trai	CO Quality —— ning Program			Excelent Calidad Oncolog




Data source

- EMR Casiopea
- Farmis Oncopharm
- IMDH
- Patient Portal (Hospital App)
- PROMs questionnaires (ePROMs)





Data source







- Implementation of PROMs forms through a hospital app
- Very few patients started therapy (only 4 patients) due to the COVID-19 pandemic
- Raw data collected but specific subanalysis of done due to the COVID-19 pandemic
- Analyze results in a period similar to that of data collection (probably between March and May 2021)





FECHA de EMISIÓN: 11/12/2020

	Resumen General Detaile Form	ularios Cerrado	os/Respondidos		Tiempos	de Res	puesta Ale	ertas HI	EM			
Resumen General			TOTAL PACIENTES									
		PACIENTES NUEVOS	PACIENTES TRABAJADOS		ENTES ORTAL	DECD 4000/ DECD 44000/					PACIENTES RESP 0%	
	PREMs y PROMs HEMATOLOGÍA	593	593	520	87,69%	63	12,12%	279	53,65%	167	32,12%	
	202012	8	472	418	88,56%	79	18,90%	0	0,00%	5	1,20%	
ĺ	202011	30	512	447	87,30%	128	28,64%	8	1,79%	294	65,77%	
ĺ	202010	34	455	401	88,13%	117	29,18%	11	2,74%	273	68,08%	
ĺ	202009	31	446	396	88,79%	126	31,82%	13	3,28%	257	64,90%	
ĺ	202008	35	428	378	88,32%	106	28,04%	9	2,38%	263	69,58%	
ĺ	202007	28	371	336	90,57%	104	30,95%	16	4,76%	216	64,29%	
	202006	20	110	102	02 640/	31	20 100/	11	10 600/	£1	E0 220/	
	202005	39	100	88	88,00%	22	25,00%	12	13,64%	54	61,369	
	202004	33	90	80	88,89%	17	21,25%	6	7,50%	57	71,259	
	202003	41	137	119	86,86%	55	46,22%	17	14,29%	47	39,509	
	202002	69	70	62	88,57%	20	32,26%	13	20,97%	29	46,77%	
İ	202001	81	207	190	91,79%	76	40,00%	19	10,00%	95	50,00%	
ĺ	201912	126	126	115	91,27%	51	44,35%	21	18,26%	43	37,39%	





FECHA de EMISIÓN: 11/12/2020

Resumen General Detalle Formularios Cerrados/Respondidos

Tiempos de Respuesta Alertas HEM

Centro	Total Alertas	Alertas Pendientes	Contestadas	<12h		12-24		>24	
FJD	689	5	684	62	9,06%	298	43,57%	324	47,37%
HCV	122	0	122	0	0,00%	72	59,02%	50	40,98%
HRJC	188	0	188	21	11,17%	62	32,98%	105	55,85%
HUIE	220	0	220	21	9,55%	118	53,64%	81	36,82%
	1219	5	1214	104	8,57%	550	45,30%	560	46,13%





FECHA de EMISIÓN 11/12/2020 8:00:50

Centro	Paciente	NHC	Edad	Nombre	Texto Indicador	Valor	Fecha Toma	Marcar LECTURA
FUNDACION JIMENEZ DIAZ			19	PROMs_Portal_PROCTCAE	¿Con qué FRECUENCIA Tuvo VÓMITOS?	A menudo	10/12/2020 11:11:03	— >
FUNDACION JIMENEZ DIAZ			19	PROMs_Portal_PROCTCAE	¿Con qué FRECUENCIA Tuvo DOLOR?	Casi siempre	10/12/2020 11:11:03	\Rightarrow
FUNDACION JIMENEZ DIAZ			19	PROMs_Portal_PROCTCAE	¿Con qué FRECUENCIA Tuvo NÁUSEAS?	A menudo	10/12/2020 11:11:03	
FUNDACION JIMENEZ DIAZ			19	PROMs_Portal_PROCTCAE	¿Con qué FRECUENCIA Tuvo SENTIMIENTOS DE TRISTEZA O DE NO ESTAR FELIZ?	Casi siempre	10/12/2020 11:11:03	
FUNDACION JIMENEZ DIAZ			19	PROMs_Portal_HMPRO	Mi ritmo de sueño ha cambiado	Mucho	10/12/2020 10:45:53	





An example

76 y.o. male. Mantle-cell lymphoma treated with Ibrutinib (an oral targeted therapy)







An example

76 y.o. male. Mantle-cell lymphoma treated with Ibrutinib (an oral targeted therapy)

Recuento		21/07/20 40125163			18/07/20 40452603			27/12/19 41032526
LEUCOCITOS (x 103 µ1) HEMATIES (x 10^6 µ1)		5.85 1.1		14.30 1.1	12.85 1.2	13.95	8.28	7.48 4.7
•	4.1	4.2	4.1		4.5	5.5	15.2	15.6
			11.9		13.5	16.6	44.3	45.2
VCM (fl)	113.9	111.3	117.8	125.2	114.4	113.7	96.3	95.6
HCM (pg)	40.6	39.6	40.6	42.1	38.1	37.7	33.0	33.0
CHCM (g/dl)	35.7	35.6	34.5	33.6	33.3	33.1	34.3	34.5
	22.4	23.8	19.7	22.0	17.8	17.1	13.9	14.2
PLAQ (x 103 µl)		120	144		138	146	140	107
VPM (fl)		12.7	12.8	12.8	12.9	13.4	12.1	12.7
RETI (%)	7.460							
	0.075							
RETI (%)		7.240						
RETI_ABS (x 10 3 μ1)		0.077						
RETI (%)			8.790					
RETI_ABS (x 10 3 μ1)			0.089					
RETI (%)						5.250		
RETI_ABS (x 103 µl)						0.077		





An example

ACTION TAKEN

Refer the patient to the Blood Bank for pretransfusional testing and schedule a blood transfusion

Check availability in Day Hospital for Packed Red Blood Cells (PRBC) transfusion

We solved patient's SAE without referring him to the ER or an unscheduled hospital admission





Conclusions

- PROM tools have decreased the number of non-scheduled consultations with de doctor and calls to the nursing or pharmacy of patients, however due to the pandemic, this information could be misinterpreted due to the fear of the patient to go to the hospital
- The value-based healthcare program in Hematology is consolidated
- We will increase the period of analysis to include more patients in the analysis and without the bias of COVID-19 outbreak





Hematologist

Hospital FJD Madrid



Implementation of a PROM tool in patients with hematological malignancies

AIM:

Implementation of PROMs forms through a hospital app

Reduce 20% of unschedule visits to ER and hospitalizations due to AEs by means of a PROM tool to identify early side effects of treatments in patients with lymphoma and CLL

TEAM:

- Nursery: Sara Raba
- Informatic team: Susana Cruz:

PROJECT SPONSORS:

Dr. Jesus Garcia-Foncillas

RESULTS:

- We think that the forms have decreased the number of non-programmed consultations with de doctor and calls to the nursing or pharmacy of patients, however due to the pandemic, said information could be altered due to the fear of the patient to go to the hospital
- The use of forms is underway in our hospital
- The comparative data has not been analyzed since the situation in dates was not comparable and will be done in the future
- •CONCLUSIONS: We think that the forms have decreased the number of non-programmed consultations with de doctor and calls to the nursing or pharmacy of patients, however due to the pandemic, said information could be altered due to the fear of the patient to go to the hospital
- The use of forms is underway in our hospital
- The comparative data has not been analyzed since the situation in dates was not comparable and will be done in the future

NEXT STEPS:

- Analyze results in a period similar to that of data collection (probably between March and May 2021)
- Collection and analysis of patient information



